At the 2-year follow-up, compared to medical treatment, RYGB increased the likelihood of albuminuria remission (albumin-to-creatinine ratio <30 mg/g creatinine) by 21.6% (95%CI 2.8–40.4), with a NNT of 5 (95%CI 2–35), increased the likelihood of CKD remission by 33.4% (95%CI 15.9–50.9), with an NNT of 3 (95%CI 2–6), and reduced BMI (MD −6.96, 95%CI −8.02 to −5.89, p<0.001). The gene discussed is ALB; the disease is chronic kidney disease.